2 withdrawn. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Methylprednisolone + ASTED, Methylprednisolone +Placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Withdrawn | Iran University of Medical Sciences | 2022-09-01 | 2022-01-10 | |
| The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) ASTED, Selenium, Placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Withdrawn | Iran University of Medical Sciences | 2019-07-15 | 2023-09-28 |
Graves Ophthalmopathy (2) · Motor Activity (1)
Autoimmune Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Endocrine System Diseases (2) · Exophthalmos (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Goiter (2) · Graves Disease (2) · Hyperthyroidism (2) · Immune System Diseases (2) · Orbital Diseases (2) · Thyroid Diseases (2) · Behavior (1)
Methylprednisolone (1) · Selenium (1)
Iran University of Medical Sciences (2)
Iran (2)